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Several matrix metalloproteinases and serine protein-
ases are upregulated in migrating keratinocytes
during cutaneous wound repair. Single cell culture
studies indicate the necessity for matrix metallopro-
teinases but not for serine proteinases in keratinocyte
locomotion. To account for epithelial±mesenchymal
interactions, an ex vivo human skin wound model
was used to investigate the contribution of matrix
metalloproteinases and serine proteinases to wound
healing by treatment with broad-spectrum inhibitors
of matrix metalloproteinases (BB-3103) or serine
proteinases (aprotinin). Human skin explants with
circular 3 mm super®cial defects were incubated in
culture medium without (controls) or with the pro-
teinase inhibitors for 7 d. BB-3103 abrogated epithe-
lialization (p < 0.001), whereas aprotinin-treated
wounds and controls were covered with new epithe-
lium. Lack of epithelialization was unlikely due to
cytotoxicity because the matrix metalloproteinase
inhibitor did neither in¯uence viability of cultured
epidermal keratinocytes nor apoptosis in wounds.
Involvement of speci®c matrix metalloproteinases
in epithelialization was analyzed by gelatin
zymography, western blotting, immunohistochemis-
try, and in situ hybridization. Wound healing was
accompanied by active matrix metalloproteinase-1
and increased active matrix metalloproteinase-2 but
irrespectively of active matrix metalloproteinase-9.
BB-3103 blocked activation of matrix metalloprotei-
nase-2 and matrix metalloproteinase-9 but not of
matrix metalloproteinase-1. Active matrix metallo-
proteinase-2 localized solely to the dermis, whereas
matrix metalloproteinase-9 was consistently found in
new epithelium. Membrane-type 1 matrix metallo-
proteinase was undetectable in wound keratinocytes.
BB-3103 and aprotinin reduced tumor necrosis fac-
tor-a in media but did not appreciably alter amounts
of other soluble regulators of matrix metalloprotei-
nases and epithelialization. Our ®ndings demonstrate
that keratinocyte migration is associated with active
matrix metalloproteinase-2 but occurs independently
of serine proteinases and active matrix metallo-
proteinase-9 in ®brin-de®cient skin wound healing.
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roteinases are involved in several processes during
wound healing. Serine proteinases such as urokinase-
plasminogen activator and plasmin, and matrix metallo-
proteinases (MMP) are the main proteinases implicated
in epidermal repair (Rùmer et al, 1996; Madlener et al,
1998; Ravanti and KaÈhaÈri, 2000). These proteinases primarily
facilitate keratinocyte movement by remodeling extracellular
matrix proteins. In addition, proteinases modulate intracellular
signaling, secretion, bioactivation, and stability of cytokines and
growth factors important for epidermal healing (Gak et al, 1992; Ito
et al, 1996; Gallea-Robache et al, 1997; Imai et al, 1997; Wakita et
al, 1997).
In plasminogen-de®cient mice, Rùmer et al (1996) demon-
strated impaired healing of wounds, although epithelialization
was not totally blocked. Using the same animal wound model,
Lund et al (1999) were able to block healing completely by
administering the synthetic MMP inhibitor GM 6001 system-
ically.
MMP are a family of at least 20 zinc-dependent endopeptidases
activated by other proteinases, e.g., plasmin and other MMP as well
as autocatalytically (Nagase and Woessner, 1999). MMP activity is
antagonized by speci®c, naturally occurring tissue inhibitors of
metalloproteinases (TIMP) and synthetic inhibitors (Vaalamo et al,
1999a). Although synthetic MMP inhibitors impair epithelial
migration in experimental studies, the importance of individual
MMP for these processes remains largely unknown (AÊ gren, 1999;
Lund et al, 1999).
In previous studies, interstitial collagenase-1 (MMP-1) was
closely related to epithelial migration in vitro (Pilcher et al, 1997)
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and in vivo (Saarialho-Kere et al, 1993; Inoue et al, 1995) in early
wound healing. Although the catalytic function of MMP-1 in
keratinocyte migration has been delineated in monocell cultures,
MMP-1 activation pathways in more complex systems are not fully
de®ned (He et al, 1989; Pilcher et al, 1997).
Less known is the role of the two gelatinases, MMP-2 and
MMP-9, in epidermal healing possibly due to varying experimental
circumstances (Salo et al, 1994; Ashcroft et al, 1997). In vitro, MMP-
9, but not MMP-2, is induced when primary human keratinocytes
are juxtaposed to type I collagen (Sarret et al, 1992). Furthermore,
conversion to a migratory keratinocyte phenotype coincided with
MMP-9 induction (McCawley et al, 1998). In contrast, Charvat et
al (1999) found that repopulation of denuded human HaCaT
keratinocyte monolayers on type I collagen was inhibited in a
concentration-dependent manner by the synthetic MMP inhibitor
BB-2516 (marimastat) and was associated with increased activity of
MMP-2, but not of MMP-9. In other in vitro studies, MMP-2
expression increased in keratinocytes and dermal ®broblasts when
cocultured (Sarret et al, 1992; Kratz et al, 1995; Zeigler et al, 1996).
These observations emphasize the complex cell±cell and cell±
matrix interactions in MMP regulation.
To address the epidermal±mesenchymal interactions, an ex vivo
human skin wound model was used to study the correlation
between spatial and temporal distribution of MMP-2, its activator
membrane-type 1 MMP (MT1-MMP) and MMP-9, their activities
and epithelialization. Wounded skin explants were treated with the
synthetic broad-spectrum hydroxamate MMP inhibitor BB-3103
or with the serine proteinase antagonist aprotinin to differentiate
the impact of MMP and serine proteinases on the re-establishment
of epidermis over a standardized defect and on MMP activation.
This model also allowed us to study these phenomena in the
absence of confounding systemic and local in¯uences such as
products from bacteria and in¯ammatory cells (Kratz and
Compton, 1997; Moll et al, 1998). Possible secondary effects of
the proteinase inhibitors on important cytokines and growth factors
were also examined.
MATERIALS AND METHODS
Ex vivo human skin wound model The ex vivo human skin wound
model was originally developed by Kratz et al (1994). The cell viability
and tissue integrity of the cultured skin explants are preserved over the
7 d experimental period in this model (Bhora et al, 1995; Jansson et al,
1996). The local ethics committee of the University of Lund (LU
508±99) approved the study. Healthy female Caucasian patients less than
30 y old, undergoing elective mammoplasty under general anesthesia,
donated skin after giving their written consent. The skin was freed from
subcutaneous fat, kept at 4°C in 0.9% NaCl (saline) and used within 4 h
after removal. The skin was rinsed three times in sterile saline, cut into
pieces of about 10 cm2 and transferred to Dulbecco's modi®ed Eagle's
medium (DMEM, D-5671; Sigma, St Louis, MO). Circular wounds,
extending about 0.5 mm into dermis, were made using a sterile 3 mm
trephine aseptically in a sterile laminar air¯ow bench. The individual
wounds were excised using a sterile 6 mm trephine with the wound in
the center (see Fig 1A). Each wound was incubated submerged in 1 ml
of complete culture medium composed of DMEM, 4.5 mg glucose per
ml, 2 mM L-glutamine, 100 U penicillin per ml, 100 mg streptomycin
per ml, and 10% (vol/vol) heat-inactivated mycoplasma-screened fetal
bovine serum (Gibco BRL, EC approved) in a 24-well plate at 37°C in
a humidi®ed atmosphere of 5% CO2/air. The calcium concentration of
the complete culture medium was determined to 1.8 mM with atomic
absorption spectrophotometry. The medium was exchanged with new
medium every other day. To study cell proliferation, 5-bromo-2¢-
deoxyuridine (BrdU; Sigma) was added at 10 mM 24 h prior to
termination day 7, at which time medium was replaced with 1 ml 10%
buffered formalin per well. Skin samples were ®xed for 18 h at room
temperature and then for another 30 h at 4°C.
MMP inhibitor BB-3103 In preliminary experiments, the water-
insoluble hydroxamate MMP inhibitor GM 6001 at 10 mM in 0.01%
dimethylsulfoxide signi®cantly (p < 0.01) reduced epithelialization
(12 6 8%, mean 6 SEM, n = 12) compared with 0.01%
dimethylsulfoxide alone added to the complete culture medium
(51 6 11%, n = 11) in the ex vivo model. To avoid the
dimethylsulfoxide addition, the water-soluble, broad-spectrum, and
hydroxamic acid-based synthetic peptide MMP inhibitor BB-3103 (Mr
475.6 Da; British Biotech Pharmaceuticals Ltd, Oxford, U.K.) was used
at 10 mM throughout in the present investigation. IC50 values indicating
the MMP inhibitory pro®le of BB-3103 were 2 nM for MMP-1, 10 nM
for MMP-2, 30 nM for MMP-3, 20 nM for MMP-7, 7 nM for MMP-
9, 4 nM for MMP-13, and the IC50 for the tumor necrosis factor
(TNF)-a converting enzyme was 800 nM as provided by the
manufacturer. The complete culture medium served as controls in the
BB-3103 series.
To assess cytotoxicity of BB-3103 on human epidermal keratinocytes,
the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) assay (1465007; Boehringer Mannheim GmbH, Mannheim,
Germany) was employed essentially as described by Newby et al (2000).
Keratinocytes, derived from a 32 y old Caucasian female, were
subcultured three times, grown in keratinocyte growth medium (KGM)-
2 to about 90% con¯uence in a 96-well plate and purchased from
BioWhittaker (BECC-0104; Verviers, Belgium). All incubation steps
were carried out at 37°C in 5% CO2/air. Keratinocytes were treated
with BB-3103 at three ®nal concentrations (in KGM-2): 1 mM, 10 mM,
and 100 mM. KGM-2 is composed of keratinocyte basal medium-2
supplemented with bovine pituitary extract, bovine insulin, human
epidermal growth factor (EGF), hydrocortisone, epinephrine, transferrin,
Figure 1. Epithelialization was blocked by
the MMP inhibitor BB-3103 but proceeded
normally with the serine proteinase inhibitor
aprotinin. Ex vivo skin wounds after 10 h (A)
and 7 d (B±D) of treatment without (A, B) or
with the MMP inhibitor BB-3103 (C), or with
the serine proteinase inhibitor aprotinin (D). (A)
Wound 10 h after establishment of skin organ
culture (control) showing activation of wound
edge keratinocytes (inset a, higher magni®cation of
left wound margin). (B) Control-treated day 7
skin wound completely covered by a two to three
cell thick keratinocyte layer (inset b, higher
magni®cation of middle wound epithelium). (C)
BB-3103-treated day 7 skin wound with no
epithelial coverage of the defect with sharp
wound edges and nonorganized dermal wound
surface (inset c, higher magni®cation of right
wound margin). (D) Wound treated for 7 d with
100 mg aprotinin per ml covered with new
epithelium (inset d, higher magni®cation of left
wound margin). Hematoxylin±eosin stain. Scale
bars: 500 mm (bar in A is for A±D); 50 mm (bar in
a is for a and b); 250 mm (bar in c is for c and d).
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gentamicin (50 mg per ml), and amphotericin-B (50 ng per ml). Control
cells were treated with KGM-2 alone. Sodium dodecylsulfate (SDS) at
100 mM in KGM-2 served as positive cytotoxic control (Newby et al
2000). After 4 h of incubation, media were replaced by 100 ml fresh
KGM-2 and 10 ml MTT at 5 mg per ml was added per well. Cells were
then incubated for a further 4 h. The formed formazan crystals by
mitochondrial dehydrogenases were solubilized according to manufactur-
er's recommendations for 16 h. DOD (OD570 nm ± OD690 nm) was meas-
ured with a scanning microplate reader.
Serine proteinase inhibitor aprotinin Aprotinin is a 6500 Da
polypeptide that inhibits plasmin, plasminogen activators, and other
serine proteinases (Fritz and Wunderer, 1983). In earlier in vitro wound
healing studies, aprotinin at 10 and 130 mg per ml inhibited contraction
of collagen type I lattices populated with human ®broblasts or
endothelial cells, respectively (Pins et al, 2000; Davis et al, 2001). Based
on these results, aprotinin was used at 10 and 100 mg per ml. Aprotinin
had an activity of 10,000 kallikrein inactivator units per ml
corresponding to 1.4 mg per ml (Trasylol, Bayer AG, Leverkusen,
Germany). One part of 1.4 mg aprotinin per ml saline or 0.14 mg
aprotinin per ml saline was mixed with 13 parts of complete culture
medium. Complete culture medium diluted with a corresponding
volume of saline served as the control to the aprotinin-treated groups.
Assessment of epithelial coverage, proliferation, and
apoptosis The formalin-®xed tissue was embedded in paraf®n, and
4 mm sections on Superfrost Plus microscopic slides were deparaf®nized
in xylene and rehydrated in descending alcohol series.
Epithelialization was evaluated in hematoxylin±eosin-stained sections
using light microscopy at a total magni®cation of 3 100. A 10 mm
eyepiece micrometer with 100 divisions was used to measure the
percentage coverage of the total wound length with at least one epithelial
cell layer (AÊ gren, 1999).
For nuclear BrdU immunodetection, the sections were boiled in
10 mM citrate buffer (pH 6.0) for 2 3 5 min in a microwave oven
(700 W). The primary mouse monoclonal antibody against BrdU (M
744; DAKO, Glostrup, Denmark) was diluted 1:100 in
Tris(hydroxymethyl)-aminomethane (Tris)-buffered saline (TBS) contain-
ing 1% (wt/vol) bovine serum albumin (BSA; Sigma), applied to the
sections for 1 h at room temperature and then rinsed twice with TBS.
The secondary biotinylated rabbit anti-mouse antibody (E354; DAKO)
was diluted 1:100 in TBS, applied to the sections for 1 h at room
temperature and then rinsed twice with TBS. The sections were then
treated with streptavidin complexed with biotinylated alkaline phospha-
tase (K391; DAKO) for 30 min at room temperature. The complex was
visualized with Fast Red (K699; DAKO). BrdU-positive cells were
enumerated in a 650 mm segment of epidermis adjacent to the respective
wound margin by light microscopy at a total magni®cation of 3 400.
To detect fragmented DNA of apoptotic cells in the paraf®n sections,
a terminal deoxytransferase mediated digoxigenin-deoxyuridine tripho-
sphate nick end labeling in situ technique (ApopTag, Oncor,
Gaithersburg, MD) was used (Airola et al, 1997). Apoptotic cells in day 7
wounds were assessed semiquantitatively on a three-point scale (0 = no;
+ = few; ++ = moderate number of apoptotic cells) in a blinded
manner.
Immunohistochemistry and in situ hybridization To study the
localization of MMP-2, MMP-9, and MT1-MMP in the wound area,
paraf®n sections were stained using mouse monoclonal antibodies that
recognize latent and active MMP-2 (IM33L; Calbiochem, Darmstadt,
Germany), MMP-9 (GE213; Diabor, Oulu, Finland) and MT1-MMP
(IM42L, Calbiochem; Vaalamo et al, 1999b). Immunostaining was
performed by the avidin±biotin-peroxidase complex technique
(Vectastain ABC Kit; Vector Laboratories, Burlingame, CA).
Diaminobenzidine was used as a chromogenic substrate and Harris
hematoxylin was used as the counterstain, which were described in detail
elsewhere (Saarialho-Kere et al, 1993). Sections were pretreated with
10 mg trypsin per ml. The MMP-2 antibody was diluted 1:200 in 1%
(wt/vol) BSA, MMP-9 was diluted 1:300 in 1% BSA, and MT1-MMP
1:40 in 3% BSA. Negative controls were performed with mouse
immunoglobulins. Three independent pathologists analyzed sections in a
blinded manner.
For in situ hybridization, an anti-sense human MT1-MMP probe was
used (Pender et al, 2000). Five micrometer sections were hybridized at
50°C for at least 18 h in a humidi®ed chamber with an 35S-labeled
probe (3 3 104 cpm per ml of hybridization buffer) (Prosser et al, 1989).
After 30 d of autoradiography, the photographic emulsion was devel-
oped. Squamous cell carcinoma samples were used as positive controls.
Samples were evaluated independently by two investigators.
Conditioning of wounds Separate skin explants, excised from the
same donors, were conditioned in parallel to the ones described above.
At days 0 and 7, the explants were conditioned for 10 h in serum-free
DMEM alone, or serum-free DMEM supplemented with 10 mM BB-
3103, 10 mg aprotinin per ml or 100 mg aprotinin per ml. At day 0, the
explants were conditioned directly after wounding and at day 7, after
three washes in serum-free DMEM. In the intervening periods the skin
explants were incubated according to the regular protocol with the
complete culture medium containing 10% fetal bovine serum. After
conditioning, the media were collected and skin samples were incubated
for a further 30 min at ambient temperature with Complete (1697498;
Boehringer Mannheim) proteinase inhibitor cocktail containing 1 mM
ethylenediaminetetraacetic acid and supplemented with 1 mM pepstatin
(253286; Boehringer Mannheim) to inhibit serine, cysteine, aspartic, and
metalloproteinases present in the tissue. The conditioned media and
explants were stored at ±70°C until analyzed.
Extraction of MMP Skin samples were thawed, weighed, and shaken
in 20 volumes of buffer containing 10 mM cacodylate-HCl pH 6.0, 1 M
NaCl, 0.01% (v/v) Triton X-100, 1 mM ZnCl2, 0.2 mg NaN3 per ml,
and 1 ml of proteinase inhibitor cocktail (539134; Calbiochem) per ml
for 18 h at 4°C (Eeckhout et al, 1986). In a complementary experiment,
extraction was carried out in the buffer devoid of the proteinase
inhibitor cocktail. Wound tissue extracts were centrifuged for 5 min at
5000 r.p.m. in a microcentrifuge and supernatant kept at 4°C until
analyzed by zymography. Freezing of extracts was avoided due to
activation of MMP by freeze±thaw cycles (unpublished data). Because
the extraction method of Eeckhout et al (1986) was originally optimized
for bone tissues, the MMP levels of the extracts were compared with
those extracted by a standard method on some wounded skin samples.
Tissues were homogenized in 20 volumes of 0.25% Triton X-100 and
10 mM CaCl2 for 1 min on ice with a Polytron PT 1200 Cl
(Brinkmann, Westbury, NY) tissue grinder and then centrifuged (AÊ gren
et al, 1998).
Protein contents were determined according to a modi®ed Lowry
assay (DC Protein Assay, 500 0112; Bio-Rad Laboratories, Hercules,
CA). Five microliters of extract were added to 25 ml of substance S and
alkaline copper tartrate solution supplemented with 200 ml Folin reagent
according to the manufacturer's instructions. BSA standard (Bio-Rad)
curves were run simultaneously (0.019±1.4 mg per ml). After 15 min,
absorbances were read at 650 nm.
Zymographic analyses of conditioned media and skin
extracts Latent and active forms of MMP-2 and MMP-9 were
determined using 0.5 mg gelatin per ml (G-8150; Sigma) as a substrate in
a 7.5% SDS±polyacrylamide gel. Thirty microliters of tissue extracts or
conditioned media were mixed with 10 ml of 4 3 sample buffer
[0.0625 M Tris±HCl pH 7.4, 2% (wt/vol) SDS, 10% (vol/vol) glycerol,
and 0.04% (wt/vol) bromophenol blue]. Aliquots of 25 ml were applied
to each lane. As positive controls for MMP-2 and MMP-9 in the assay, a
human MMP-2 (50 ng per ml)/MMP-9 (50 ng per ml) standard
(19101670; Chemicon International, Temecula, CA) was run in parallel
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lanes. In selected zymographies, gelatinase speci®city was checked by
adding dithiothreitol at 50 mM (®nal concentration) to the sample buffer
(Peeters-Joris et al, 1998). Samples were electrophoresed using the mini-
PROTEAN II apparatus (Bio-Rad) at 50 mA constant current. After
electrophoresis, the gels were washed three times in 2.5% Triton X-100
and incubated in a buffer composed of 5 mM CaCl2, 1 mM ZnCl2,
50 mM Tris±HCl pH 7.4, 0.1% Triton X-100, and 0.003 M NaN3 for
18 h at 37°C in a closed container with continuous shaking. BB-3103
was added to the buffer at 10 mM in representative zymograms.
Zymograms were stained in 0.25% Coomassie Brilliant Blue R-250, 10%
acetic acid and 45% methanol for 30 min and destained for 30 min in
20% acetic acid, 20% methanol, 17% ethanol, and 0.6% diethylether
(Kleiner and Stetler-Stevenson, 1994). Gels were mounted, dried, and
scanned. The intensity of the gelatin degradation bands was subjected to
semiquantitative densitometric analysis (Eagle Eye II, Stratagene Eagle
Sight, Stratagene Ltd., Cambridge, UK) and expressed in arbitrary units.
To study if residual BB-3103 in samples per se interfered with the
detection of MMP activity by zymography, BB-3103 at 10 mM was
added to day 7 conditioned media from control-treated wounds.
Conditioned media with or without BB-3103 were then incubated for
30 min at room temperature followed by zymographic analysis.
Western immunoblotting Tissue extracts, mixed with an equal
volume of 2 3 sample buffer containing 50 mM 2-mercaptoethanol,
were boiled for 5 min. Samples, standards for MMP-1, MMP-2, and a
recombinant protein molecular weight marker (RPN800, Amersham
Pharmacia Biotech, Buckinghamshire, U.K.) were electrophoresed on a
7.5% SDS±polyacrylamide gel and electroblotted on to nitrocellulose
membranes (Bio-Rad). The membranes were blocked overnight in TBS
containing 5 g Tween 20 and 50 g milk powder per liter at 4°C and
then incubated with mouse monoclonal antibodies 1:5000 against MMP-
1 (MAB1346; Chemicon), 1:1000 against MMP-2 (MAB3308;
Chemicon) or MT1-MMP (AB815; Chemicon) at 1:1000 dilutions for
1 h at room temperature. After washing three times for 20 min in TBS
with 5 g Tween 20 per liter (TBS-T), membranes were incubated with
a horseradish peroxidase-conjugated secondary anti-mouse antibody
(315-035-045; Jackson Immuno Research, West Grove, PA) in TBS-T
and 50 g milk powder per liter washed two times in TBS-T and
developed with the ECLTM western blotting analysis system (Amersham
Pharmacia Biotech).
Cytokine and growth factor analyses of conditioned
media Sandwich enzyme-linked immunosorbent assays were used to
determine human TNF-a, interleukin (IL)-1b, EGF, hepatocyte growth
factor (HGF), keratinocyte growth factor (KGF), and tumor growth
factor (TGF)-b1 in incubation or conditioned media. The high-
sensitivity TNF-a kit (RPN 2788) from Amersham Pharmacia Biotech
employed an ampli®cation reagent for the enhancement of binding of a
mature form of TNF-a in incubation media. This antibody pair is
capable of recognizing TNF-a even in the presence of superphysiologic
concentrations of both types of soluble TNF-a receptors. Quantikine
enzyme-linked immunosorbent assay kits from R&D Systems
(Minneapolis, MN) were used to determine active human forms of
epidermal growth factor (DEG00), KGF (DKG00), HGF (DHG00), IL-
1b (DLB50), and TGF-b1 (DB100) in conditioned media according to
the manufacturer's instructions. Prior assaying for TGF-b1, the samples
were treated with 0.17 M HCl for 10 min at room temperature and
then neutralized with 0.17 NaOH/0.07 M HEPES. To check for
interference with the different enzyme-linked immunosorbent assay kits,
representative conditioned media from all groups and the proteinase
inhibitors BB-3103 at 10 mM and aprotinin at 100 mg per ml alone were
added to standard antigens diluted appropriately in separate wells and run
in parallel to the samples.
Statistical analyses Student's t test for unpaired observations was used
for comparisons between the groups. p < 0.05 was considered statistically
signi®cant. Numerical data are presented as mean 6 SEM.
RESULTS
Microscopic ®ndings Epithelial resurfacing without or with
treatment with proteinase inhibitors was investigated here in an ex
vivo skin wound model. There was a striking difference in epithelial
wound healing between controls and wounded skin explants
treated with the synthetic peptide hydroxamate MMP inhibitor
BB-3103 at 10 mM. In the control group, a few keratinocytes at
wound edges had adopted an elongated morphology after 10 h
incubation (Fig 1A, inset a). After 7 d, the wound was covered
with a two to three cell thick keratinocyte layer (Fig 1B), whereas
no or only minimal epithelial outgrowth from the sharp wound
Figure 2. The MMP inhibitor BB-3103 abrogated mean epithelial
coverage of central wounds in skin explants, whereas the serine
proteinase inhibitor aprotinin did not reduce epithelialization
signi®cantly after 7 d. Wounded skin explants were incubated in
medium alone (0, n = 10), medium supplemented with 10 mM of the
MMP inhibitor BB-3103 (n = 6) or medium supplemented with the
serine proteinase inhibitor aprotinin at 10 mg per ml (n = 9) or 100 mg
per ml (n = 9). Statistically signi®cant (***) reduction of
epithelialization, expressed in percentage (%), was found in MMP
inhibitor-treated group compared with the control group, whereas no
signi®cant differences between aprotinin-treated groups and controls
were found. t test results: control vs BB-3103, p < 0.001; control vs
10 mg aprotinin per ml, p = 0.40; control vs 100 mg aprotinin per ml, p
= 0.24. Error bars: SEM.
Figure 3. BB-3103 treatment did not increase apoptosis. Labeling
of fragmented DNA by in situ hybridization was used to identify
apoptotic cells (dark brown nuclei). (A) Control-treated day 7 wound
with apoptotic epithelial cells (arrows). (B) BB-3103-treated day 7 wound
with apoptosis in basal but not in wound edge keratinocytes. Large arrows
depict corresponding spots in A and B. Scale bar: 25 mm.
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edges was observed in the BB-3103-treated group (Fig 1C).
Furthermore, collagen bundles at the rough wound surface and
gaping wound edges dominated in the BB-3103 group. These
results were con®rmed in three independent experiments with
different skin donors.
Because of the previously reported importance of the plasmino-
gen system on epithelialization (Rùmer et al, 1996; Lund et al,
1999), skin wounds were also incubated ex vivo with the serine
proteinase inhibitor aprotinin at 10 mg per ml or 100 mg per ml.
Keratinocyte coverage and other histologic features in the aprotinin
groups resembled those of controls after 7 d of treatment (Fig 1D).
Quantitative morphometry showed no statistically signi®cant
impairment of healing with either dosages of aprotinin, whereas
BB-3103 treatment inhibited resurfacing profoundly and signi®-
cantly (p < 0.001) compared with controls (Fig 2). Taken together,
these ®ndings show that epithelialization of human skin wounds ex
vivo is mainly dependent on MMP and not on serine proteinases.
To discern migration from proliferation, the thymidine analog
BrdU was immunolocalized in the wounds after a 24 h BrdU pulse.
In controls, the highest proliferative activity was seen in the
epithelium over the wound and at wound edges, whereas only a
few basal cells of distant nonwounded epidermis, epidermal
appendages, ®broblasts, and endothelial cells were synthesizing or
had synthesized DNA. Similar labeling was obtained when adjacent
sections were immunostained for the endogenous proliferation
marker Ki67 (data not shown). To enable comparison among the
groups, BrdU-positive cells were counted in the epidermis at
wound edges. BB-3103 increased proliferation (2.7 6 0.6 BrdU-
positive cells per 650 mm epidermis) signi®cantly (p < 0.05)
compared with the control (1.1 6 0.3). Conversely, there were
no signi®cant differences between controls and the aprotinin
groups with respect to epithelial proliferation.
To study the effects of BB-3103 on apoptosis in epithelial and
mesenchymal cells, skin samples were stained with a terminal
deoxytransferase mediated digoxigenin-deoxyuridine triphosphate
nick end labeling in situ technique and scored semiquantitatively.
There were no differences between BB-3103- and control-treated
groups (Fig 3A, B).
Figure 4. MMP-9 but not MMP-2 immunolocalized in the epidermal sheet. Control-treated (A±E), BB-3103-treated (F, G), and aprotinin-
treated (H, I) human skin wounds were immunostained using mouse monoclonal antibodies against human MMP-2 and MMP-9 as described under
Materials and Methods. The microphotographs are arranged with MMP-2-stained sections to the left (A, D, F, H) and adjacent sections stained for
MMP-9 to the right in the panel (B, E, G, I). At 10 h, wound edge keratinocytes (arrow) were negative for MMP-2 (A) and MMP-9 (B) and showed
similar staining as adjacent sections treated without primary antibodies but with mouse IgG (C). After 7 d of treatment, MMP-2 was not localized in
the epidermal tip (D) but to ®broblasts (arrows) in the stroma (D¢), whereas intracellular MMP-9 immunostaining was observed in advancing epithelium
(E). BB-3103-treated wounds with no MMP-2-positive epithelial cells (F) but MMP-9-positive staining in the few keratinocytes at the wound edge
(arrow) (G). Aprotinin-treated wounds (100 mg per ml) showed similar immunoreactivity as control-treated wounds for MMP-2 in dermis (H) and for
MMP-9 (arrow) (I) in keratinocytes. Scale bars: 50 mm (D); 25 mm (A±C, E±I); 12.5 mm (D¢).
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Cytotoxicity assessment of BB-3103 on cultured cells To
exclude the possibility that impaired epithelialization with the
MMP inhibitor was due to a cytotoxic effect, monolayers of human
epidermal keratinocytes were exposed to BB-3103 and cell viability
measured with the MTT assay. Compared with control-treated
human epidermal keratinocytes (n = 12), the DOD values for
1 mM BB-3103 (p = 0.294) were 94.3 6 4.7% (mean 6 SEM,
n = 8), for 10 mM BB-3103 (p = 0.267) 94.7 6 3.6% (n = 12),
and for 100 mM BB-3103 (p = 0.373) 93.9 6 6.9% (n = 8). The
positive cytotoxic SDS control decreased (p < 0.001) DOD values
to 28.6 6 3.4% (n = 7) compared with control-treated cells. No
cytotoxicity of 10 mM BB-3103 was seen either when
keratinocytes were cultured in regular DMEM with 10% fetal
bovine serum (95.2 6 3.3%, n = 12, p = 0.340) or when tested
on cultured human dermal ®broblasts (97.6 6 2.4%, n = 8,
p = 0.478).
Immunohistochemistry and in situ hybridization To study
epidermal±dermal distributions of MMP-2, MMP-9, and MT1-
MMP, immunohistochemistry was performed. In addition, in situ
hybridization was carried out for MT1-MMP. MMP-2 and MMP-
9 showed distinct and different immunostaining patterns. At 10 h,
¯at and elongated keratinocytes at wound edges were
immunonegative for both MMP-2 and MMP-9 (Fig 4A, B).
Only background staining was seen in control sections treated
identically with mouse immunoglobulins instead of primary
antibodies (Fig 4C). At day 7, the epithelial tip was MMP-2
negative, whereas MMP-2 was predominantly found in dermal
®broblasts of control groups (Fig 4D, inset D¢). MMP-9 was
detected in advancing keratinocytes and, occasionally, in
macrophage-like cells (Fig 4E). A similar distribution of the two
gelatinases was found in MMP inhibitor-treated groups. Treatment
with BB-3103 also showed expression of MMP-2 in dermis
(Fig 4F) and MMP-9 in keratinocytes of the few samples
containing a small epithelial tongue (Fig 4G). In the aprotinin-
treated groups, MMP-2 was located in dermis (Fig 4H), whereas
MMP-9 was detected in wound edge keratinocytes (Fig 4I).
By in situ hybridization, MT1-MMP mRNA was undetectable
in the advancing epithelium, but was detected in dermis, of the
control, aprotinin, or BB-3103 groups (Fig 5A±F). In contrast,
squamous cell carcinomas showed a strong signal for MT1-MMP
(data not shown). No MT1-MMP protein was detected in wound
epithelium (data not shown).
Enzyme analyses of tissue extracts Because the antibodies
used for the immunohistochemical studies did not distinguish
Figure 5. MT1-MMP is expressed in dermis but not in epithelium. In situ hybridization with an anti-sense MT1-MMP probe was performed in
control- (A, B), BB-3103- (C, D), and aprotinin- (E, F) treated human skin wounds as described under Materials and Methods. (A) Keratinocytes in the
epithelial tongue of control wounds (large arrow) were negative for MT1-MMP mRNA, whereas MT1-MMP was present in stromal cells (arrows). (B)
Corresponding bright-®eld image. The asterisks mark autoradiographic artifacts. (C) No MT1-MMP mRNA was detected in wound edge keratinocytes
with BB-3103 treatment either (arrow). (D) Corresponding bright-®eld image. (E) MT1-MMP mRNA was expressed in stromal cells of aprotinin-
treated wounds (arrow), whereas wound keratinocytes were negative (large arrow). (F) Corresponding bright-®eld image. Scale bar: 25 mm.
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between latent and active MMP, samples were also analyzed by
zymography. The method of Eeckhout et al (1986) was used
throughout because it yielded 3-fold more active and latent MMP-
2 and MMP-9 compared with a standard method (AÊ gren et al,
1998) as assessed by zymography (Fig 6B). Furthermore, active as
well as inactive MMP-2 and MMP-9 enzymatic species displayed
the same intensity regardless of the presence or absence of a
proteinase inhibitor cocktail during the extraction procedure (data
not shown). Altogether, these ®ndings indicate that gelatinases
were not activated during extraction from the skin explants. In
another study, collagenases extracted from bone were not activated
either using the same method (Eeckhout et al, 1986).
In tissue extracts, the predominant MMP was MMP-2 at the start
of the experiment (Fig 6A). The ratio of active to total MMP-2 in
control groups increased after 7 d of incubation. The identity of
MMP-2 was veri®ed by the identical position of the human MMP-
2 standard on the zymograms, abolished gelatinolytic activity on
zymogram with 50 mM dithiothreitol during electrophoresis
(Peeters-Joris et al, 1998), with BB-3103 in incubation buffer and
by western immunoblotting (Fig 7A). In the hydroxamate-treated
group, the amount of active MMP-2 did not increase over the 7 d
incubation period. In three independent experiments using differ-
ent skin donors, the percentage of active to total MMP-2 was
found signi®cantly (p < 0.05) lower (13.1 6 5.2%) compared with
control (53.9 6 9.2%) at day 7 as assessed by densitometry (Fig 6A
and Fig 8A). Aprotinin treatment did not in¯uence the amount of
active MMP-2 compared with control.
MT1-MMP, the cell-bound MMP that activates MMP-2, was
present in about equal amounts in control- and BB-3103-treated
skin explants as analyzed by western immunoblotting (Fig 7B).
Less of the total MMP-9, entirely in latent form, than of MMP-2
was found day 0. After 7 d of treatment the total amount of MMP-
9 was increased 13-fold in controls (Figs 6A and 8B). A lysis band
corresponding to active MMP-9, encompassing 10±15% of total
MMP-9 activity, appeared in controls and in the skin explants
treated with the lowest concentration of aprotinin (10 mg per ml)
(Figs 6A and 8B). No active MMP-9 gelatinolytic bands were
visible in explants treated with 100 mg aprotinin per ml or with
BB-3103 (Fig 6A).
By western blotting analysis, active and latent bands of MMP-1,
identi®ed by the same positions as recombinant human MMP-1
standard, were found at similar levels in tissue extracts of control
and BB-3103 groups (Fig 7C).
Zymography of conditioned media Although conditioned
media also contained active MMP-2, the ratio active to latent
MMP-2 was lower than that found in the tissue in all groups and
time points, which was an observation made earlier for other
connective tissues (Creemers et al, 1998). In the BB-3103-treated
group, active MMP-2 decreased in contrast to the control and
aprotinin groups, where active MMP-2 increased from 10% at day
0 to about 50% at day 7 (Fig 6D). A control experiment showed
that BB-3103 did not interfere with the zymographic detection of
MMP-2 (Fig 6C), which implies that BB-3103 dissociated
Figure 6. Representative zymograms of tissue extracts and
conditioned media. (A, B) Tissue extracts (20 ml per slot),
corresponding to 1.6 mg of total proteins, were loaded into each slot. (C,
D) Conditioned media (20 ml) were loaded into each slot. The samples
were analyzed as described in Materials and Methods. (A, D) Lanes 1±4,
day 0; lanes 5±8, day 7. Lanes 1 and 5, control; lanes 2 and 6, aprotinin
10 mg per ml; lanes 3 and 7, aprotinin 100 mg per ml; lanes 4 and 8, BB-
3103. (B) Recovery of gelatinases by the extraction method of Eeckhout
et al (1986) (lane 2) was increased compared with standard method (lane
1). (C) Day 7 conditioned media incubated for 30 min without (lane 1)
or with BB-3103 (lane 2). The positions of MMP-2 (lower bands) and
MMP-9 (upper bands) human standards are indicated to the right with
black arrows for latent enzymes and white arrows for active enzymes. Figure 7. Western immunoblotting of MMP-2, MT1-MMP, and
MMP-1 in tissue extracts. Extracts of day 7 wounded explants were
separated on 7.5% SDS±polyacrylamide gel electrophoresis, proteins
electroblotted onto nitrocellulose membrane, which was probed with
monoclonal antibodies against human MMP-2 (A), MT1-MMP (B), and
MMP-1 (C) (see Materials and Methods). (C) Upper doublets represent
glycosylated (upper band) and unglycosylated (lower band) forms of
latent MMP-1 and lower doublets of active MMP-1, respectively
(Saarinen et al, 1994). Position of molecular weight markers are indicated
to the right in kDa. Lanes 1 and 2, control; lanes 3 and 4, BB-3103.
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completely from active MMP-2 at electrophoresis. Active MMP-9
could not be detected in conditioned media of any group (Fig 6D).
Addition of BB-3103 at 10 mM to the incubation buffer abolished
all gelatinolytic activity in the zymograms (data not shown).
Cytokines and growth factors Important cytokines and
growth factors were determined to study possible secondary
effects of the proteinase inhibitors. BB-3103 treatment reduced
the levels of TNF-a in incubation media of wounded explants
compared with control-treated explants over the ®rst 10 h. The
amount of TNF-a in the incubation media was also reduced by
treatment with 100 mg aprotinin per ml (Table I). The inhibitory
effect of BB-3103 on TNF-a levels persisted and 12 pg TNF-a per
ml were detected in the BB-3103 group compared with a control
value of 63 pg TNF-a per ml over a 48 h incubation period.
The immunoreactive levels of mature IL-1b, HGF, KGF, or
TGF-b1 in serum-free DMEM media of explants conditioned for
10 h differed as a function of time. IL-1b levels were unaltered (p
= 0.97), whereas KGF (p < 0.001) and TGF-b1 (p < 0.01)
increased and HGF (p < 0.001) decreased signi®cantly from day 0
to day 7 (Table II). Treatment with BB-3103 and aprotinin did
not in¯uence these levels in conditioned media (Table II). EGF
levels were below the detection limit (0.7 pg per ml) in all groups.
The different standard antigens were recovered (100%) in the
presence of BB-3103 or aprotinin alone or in the various
incubation and conditioned media.
DISCUSSION
The effect of proteinases on human epidermal wound healing was
investigated here using inhibitors of MMP (BB-3103) and serine
proteinases (aprotinin) in a standardized, ex vivo human skin wound
model. Inhibition of MMP with BB-3103 blocked healing
completely, whereas aprotinin did not inhibit epithelialization
signi®cantly, indicating the requirement for one or more MMP in
epidermal wound healing. We therefore focused on MMP-1,
MMP-2, MMP-9, and MT1-MMP, although other MMP have
also been implicated in epithelialization (Ravanti and KaÈhaÈri, 2000;
Rechardt et al, 2000).
MMP-1 has been ascribed a crucial role in keratinocyte
migration (Pilcher et al, 1997). In our wound model, keratinocytes
express MMP-1 during early epithelialization, whereas MMP-1
mRNA increases in ®broblasts later (day 7) (Inoue et al, 1995). The
MMP inhibitor did not alter MMP-1 protein levels in day 7 tissue.
Furthermore, the presence of active MMP-1 in the BB-3103 group
indicates that MMP-1 activation in skin is an MMP-independent
process as suggested by others (He et al, 1989). Despite similar
protein levels, the enzymatic activity of MMP-1 was presumably
blocked by the MMP inhibitor. On the other hand, BB-3103
prevented activation of both MMP-2 and MMP-9, whereas
aprotinin blocked activation of MMP-9 but not of MMP-2. This
can be explained by that the majority of MMP ± except for MMP-
2 ± are directly activated by plasmin in vitro (He et al, 1989;
Murphy et al, 1992; Carmeliet et al, 1997; Creemers et al, 1998).
The function of MMP-9 is obscure because healing was
unimpeded despite no active MMP-9 with aprotinin. Our
immunohistochemical studies showed that MMP-9, but not
MMP-2, was found in migrating keratinocytes. In another
human ex vivo study, migrating bronchial epithelial cells were
MMP-9 immunopositive (Legrand et al, 1999). Keratinocyte-
derived MMP-9 preferentially bound to the cell surface but not to
the extracellular matrix molecules deposited by human mucosal
keratinocytes in vitro, implying no catalytic role of MMP-9 (MaÈkelaÈ
Figure 8. Active MMP-2 and active MMP-9 in tissue extracts
decreased with the MMP inhibitor BB-3103 over 7 d. (A) MMP-2;
(B) MMP-9. The amount of latent (open bars) and active (®lled bars)
MMP-2 and MMP-9 at day 0 (0) and day 7 (7) was determined by
densitometry of scanned zymograms in Fig 6A. Control, medium alone;
A10, 10 mg aprotinin per ml; A100, 100 mg aprotinin per ml; BB-3103,
10 mM BB-3103.
Table I. TNF-a levelsa in incubation media after the initial
10 h incubation at day 0
Control BB-3103
Aprotinin (mg per ml)
10 100
310 6 110b 50c 410c 80c
afg per ml.
bMean 6 SEM (n = 4).
cn = 2.
Table II. IL-1b, HGF, KGF, and TGF-b1 levelsa in
conditioned media at days 0 and 7
Controlb BB-3103c
Aprotinin (mg per ml)
10c 100c
Day 0
IL-1b 1.5 6 0.3 2.4 1.7 1.8
HGF 1700 6 420 1380 1400 1430
KGF 4.6 6 0.4 6.4 7.1 9.0
TGF-b1 17 6 2.6 20 46 31
Day 7
IL-1b 1.5 6 0.2 1.7 1.2 1.0
HGF 300 6 44 460 330 390
KGF 12 6 0.9 7.5 14 14
TGF-b1 70 6 8.0 77 75 68
apg per ml.
bMean 6 SEM. Day 0, n = 4; day 7, n = 8.
cn = 2.
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et al, 1998); however, migration of human bronchial epithelium
was associated with degradation of type IV collagen by active
MMP-9 (Legrand et al, 1999). In the wounds studied here,
keratinocytes synthesize new matrix molecules, including laminins
but not immunodetectable amounts of type IV collagen (Jansson et
al, 1996). Speci®c cleavage of laminin-5 by active MMP-2 induced
migration of normal human breast epithelial cells, whereas active
MMP-9 did not infer a migratory phenotype in a transmembrane
assay. Epithelial migration was also blocked completely by adding
BB-94, an analogous hydroxamate to BB-3103 (Giannelli et al,
1997). Apparently, the type of matrix molecules and epithelium
governs the requirement for MMP-9 in epithelialization.
Migration of transformed epithelial cell lines has been attributed
to the expression of MT1-MMP (Koshikawa et al, 2000). In this
study, MT1-MMP transcript or protein were detected in dermis
but not in advancing epithelium. Kidney epithelial cells (MDCK)
overexpressing MT1-MMP showed similar migration rates on type
I collagen lattices as nontransfected cells (Hotary et al, 2000). In
contrast, MT1-MMP transfectants penetrated extensively into the
three-dimensional collagen matrix. These ®ndings indicate that
MT1-MMP is important for epithelial cells to move into, but not
across, collagen matrices, a hallmark of tumor invasion.
An issue was that the effects of the MMP inhibitor on wound
healing were secondary to reduced levels of pro-in¯ammatory
cytokines because hydroxamate inhibitors such as BB-3103
decrease shedding of membrane-anchored cytokines such as
TNF-a but not of interleukins (Barker et al, 1991; Gallea-
Robache et al, 1997). Accordingly, the levels of the mature form of
TNF-a in the medium decreased with BB-3103 treatment,
whereas IL-1b levels were unchanged compared with controls.
The reduced TNF-a amounts also found with aprotinin treatment
suggest that TNF-a was not a decisive factor for epidermal healing
in our model. Exogenous TNF-a did not affect keratinocyte
proliferation or differentiation in a skin-equivalent model
(Fransson, 2000).
TNF-a was implicated as an activator of MMP-2 via MT1-
MMP induction in organ-cultured human skin (Han et al, 2000).
This activation pathway was unlikely to operate in our system
because MT1-MMP levels were similar in BB-3103-treated
wounds and controls.
Growth factors regulate both MMP and wound healing (Sato et
al, 1995; Zeigler et al, 1996; McCawley et al, 1998). The
concentrations of immunoreactive mature HGF, KGF, and TGF-
b1 in conditioned media were similar in the different treatment
groups. The increased proliferation in marginal epidermis in BB-
3103-treated explants could be explained by the displacement of
TIMP by the synthetic inhibitor resulting in more unbound,
mitogenic TIMP (Buisson-Legendre et al, 2000). Furthermore,
these observations indicate that epithelial migration rather than
proliferation is the major closure mechanism of the ex vivo wounds.
The abolished epithelialization was unlikely to have been due to
a cytotoxic effect on keratinocytes by the MMP inhibitor. These
results agree with in vitro studies demonstrating that BB-3103 was
not toxic on human endothelial cells (Mackarel et al, 1999).
Different experimental models could explain the discrepancy
between our ®ndings and the in vivo results in mice of Lund et al
(1999). Our interest was to elucidate the effect of serine proteinases
speci®cally in epidermal healing of acute human wounds free from
in¯uences of ®brin and in¯ammatory cells. For example, the effect
of aprotinin on clot formation would make interpretation dif®cult.
In our ex vivo excisional wound model, keratinocytes move over a
collagenous matrix to cover a circle-shaped epidermal defect,
whereas migration occurs mainly over a ®brin-rich provisional
matrix in full-thickness incisional wounds. In support of our
®nding, Ando and Jensen (1996) demonstrated that movement of
human keratinocytes was unrelated to the proteolytic activities of
the urokinase-plasminogen activator/plasminogen system. In add-
ition, aprotinin at 100 mg per ml did not in¯uence the random
motility or dispersion of single human keratinocytes (Ando and
Jensen, 1996; McCawley et al, 1998). On the other hand, plasmin
may contribute to wound contraction via MMP activation (Pins et
al, 2000; Davis et al, 2001).
In summary, the broad-spectrum MMP inhibitor BB-3103
blocked epithelialization completely in a human wound model ex
vivo. Aprotinin, which inhibits plasmin and other serine proteinases
and MMP-9 activation, in¯uenced neither keratinocyte migration
nor MMP-2 activation in ®brin-de®cient skin wound healing.
Collectively, serine proteinases are not per se prerequisite for
epithelialization of human skin wounds, whereas MMP (except for
MMP-9) are. More selective synthetic MMP inhibitors are being
explored in our laboratory to determine the requirement of speci®c
MMP in epithelialization.
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